What if COVID-19 affects the child: which weapons and how to use them

Eur Rev Med Pharmacol Sci. 2021 Apr;25(8):3325-3337. doi: 10.26355/eurrev_202104_25744.

Abstract

Since the reports in Wuhan (China), in December 2019, of the first cluster of cases of pneumonia caused by the new Coronavirus called 2019-nCoV or SARS-CoV-2, there has been a pandemic spread of the infection. By now, we have no specific therapy to counteract this emergency. The latest epidemiological data suggest that children are just as likely as adults to get infected by the virus. Most of them show mild clinical pictures or are completely asymptomatic, but there is an increased risk for severe disease in infancy (<12 months of age) and in children with underlying medical conditions. In this article, research achievements on the treatment of pediatric SARS-CoV-2 infection are examined.

Publication types

  • Review

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Adolescent
  • Age Factors
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Anticoagulants / therapeutic use
  • Antiviral Agents / therapeutic use*
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment
  • COVID-19 Serotherapy
  • Carrier State
  • Child
  • Child, Preschool
  • Chloroquine / therapeutic use
  • Continuous Renal Replacement Therapy
  • Drug Combinations
  • Extracorporeal Membrane Oxygenation
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunization, Passive
  • Immunoglobulins, Intravenous / therapeutic use
  • Immunologic Factors / therapeutic use*
  • Infant
  • Infant, Newborn
  • Interferon-alpha / therapeutic use
  • Lopinavir / therapeutic use
  • Oseltamivir / therapeutic use
  • Receptors, Cell Surface / therapeutic use
  • Respiration, Artificial
  • Ribavirin / therapeutic use
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Severity of Illness Index
  • Thrombosis / prevention & control

Substances

  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antiviral Agents
  • Drug Combinations
  • Glucocorticoids
  • Immunoglobulins, Intravenous
  • Immunologic Factors
  • Interferon-alpha
  • Receptors, Cell Surface
  • Robo3 protein, mouse
  • lopinavir-ritonavir drug combination
  • Oseltamivir
  • Lopinavir
  • remdesivir
  • Adenosine Monophosphate
  • Ribavirin
  • Hydroxychloroquine
  • Chloroquine
  • tocilizumab
  • Ritonavir
  • Alanine